Please use this identifier to cite or link to this item: http://conacyt.repositorioinstitucional.mx/jspui/handle/1000/7842
Effectiveness of a nation-wide COVID-19 vaccination program in Mexico
CLEMENTE HUMBERTO ZÚÑIGA GIL
CHRISTIAN ARTURO ZARAGOZA JIMÉNEZ
EDGAR GABRIEL GARCIA RODRIGUEZ
Omar Yaxmehen Bello-Chavolla
Neftali Eduardo Antonio Villa
Sergio Iván Valdés-Ferrer
Daniel Ramírez García
Luisa Fernández Chirino
Carlos Fermín Martínez
Javier Mancilla-Galindo
Ashuin Kammar-García
José Alberto AVILA-FUNES
Miguel García-Grimshaw
Santa Elizabeth Ceballos Liceaga
Guillermo Carbajal Sandoval
Ricardo Cortes-Alcala
Gustavo Reyes-Terán
Hugo López-Gatell Ramírez
Luis Miguel Gutiérrez Robledo
José Antonio Montes González
Acceso Abierto
Atribución-NoComercial-SinDerivadas
https://doi.org/10.1101/2022.04.04.22273330
BACKGROUND Vaccination has been effective in ameliorating the impact of COVID-19. However, estimation of vaccine effectiveness (VE) is still unavailable for some widely used vaccines and underrepresented groups. Here, we report on the effectiveness of a nation-wide COVID-19 vaccination program in Mexico. METHODS We used a test-negative design within a national COVID-19 surveillance system to assess VE of the BNT162b2, mRNA-12732, Gam-COVID-Vac, Ad5-nCoV, Ad26.COV2.S, ChAdOx1 and CoronaVac vaccines, against SARS-CoV-2 infection, COVID-19 related hospitalization and death for adults ≥18 years in Mexico. VE was estimated using Cox proportional hazard models considering time-varying vaccination status in partial and fully vaccinated individuals compared to unvaccinated adults, adjusted by age, sex, comorbidities and municipality. We also estimated VE for adults ≥60 years, for cases with diabetes and comparing periods with predominance of variants B.1.1.519 and B.1.617.2. RESULTS We assessed 793,487 vaccinated compared to 4,792,338 unvaccinated adults between December 24th, 2020, and September 27th, 2021. VE against SARS-CoV-2 infection was highest for fully vaccinated individuals with mRNA-12732 (91.5%, 95%CI 90.3-92.4) and Ad26.COV2.S (82.2%, 95%CI 81.4-82.9), whereas for COVID-19 related hospitalization were BNT162b2 (84.3%, 95%CI 83.6-84.9) and Gam-COVID-Vac (81.4% 95%CI 79.5-83.1) and for mortality BNT162b2 (89.8%, 95%CI 89.2-90.2) and mRNA-12732 (93.5%, 95%CI 86.0-97.0). VE for all evaluated vaccines was reduced for adults ≥60 years, people with diabetes, and in periods of Delta variant predominance. CONCLUSIONS All evaluated vaccines were effective against SARS-CoV-2 infection and COVID-19 related hospitalization and death. Mass vaccination campaigns with multiple vaccine products are feasible and effective to maximize vaccination coverage.
Medrxiv
05-04-2022
Preimpreso
medrxiv.org/
Inglés
VIRUS RESPIRATORIOS
Appears in Collections:Artículos científicos

Upload archives